Combination of an agonistic anti-CD40 monoclonal antibody or a CD40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis
Bureau, Fabrice,Wallemacq, Hughes,Boutet, Philippe,Lekeux, Pierre
申请号：
AU2011310887
公开号：
AU2011310887A1
申请日:
2011.09.01
申请国别(地区):
AU
年份:
2013
代理人:
摘要：
The present invention relates to the provision of a combination of an agonistic anti-CD40 monoclonal antibody or a CD40 ligand and inactivated or attenuated bacteria selected from the group consisting of Staphylococcus, Streptococcus, Listeria or Escherichia for use in the treatment and/or prevention of mastitis. In particular, the agonistic anti-CD40 monoclonal antibody as provided comprises a) an immunoglobulin heavy chain variable domain (VH) which comprises the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence SEQ ID NO:1: SYAMS, said CDR2 having the amino acid sequence SEQ ID NO:2: SIGSGGGTYYPDSVKD, and said CDR3 having the amino acid sequence SEQ ID NO:3: AYYRNHRGSVMDY and b) an immunoglobulin light chain variable domain (VL) which comprises the hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence SEQ ID NO:4: KASQTVDYDGDSYMN, said CDR2 having the amino acid, sequence SEQ ID NO:5: SASNLES, and said CDR3 having the amino acid sequence SEQ ID NO:6: QQSTEDPPT for use in the treatment and/or prevention of mastitis or variants thereof capable of inducing CD40 receptor aggregation. Furthermore, the present invention relates to a nucleic acid molecule encoding the agonistic anti-CD40 monoclonal antibody, a vector comprising said nucleic acid and a host comprising said vector. Finally, the present invention relates to a vaccine comprising the combination of an agonistic anti-CD40 monoclonal antibody and inactivated or attenuated bacteria selected from the group consisting of Staphylococcus, Streptococcus, Listeria or Escherichia.
